Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Graft-Versus-Host Disease

Use of antithymocyte globulin for treatment of steroid-refractory acute graft-versus-host disease: an international practice survey

Bone Marrow Transplantation volume 28, pages 945–950 (2001)Cite this article

Abstract

Antithymocyte globulin (ATG) is accepted as a treatment option for steroid-refractory acute graft-versus-host disease (GVHD). We conducted an international survey to determine how steroid refractoriness is defined and how ATG is used in clinical practice. Responses were received from 153 centers in 36 countries. The most common threshold steroid dose to define steroid refractoriness was 2 mg/kg/day (67% of respondents), and the median duration of treatment before failure was declared varied from 3 to 5.5 days, depending on whether failure was defined as ‘progressed’, ‘not improved’ or ‘not resolved’. The threshold corticosteroid dose was significantly higher in pediatric centers than in adult or combined programs (P = 0.003). ATG was used routinely for treatment of steroid-refractory GVHD by 67% of the respondents. Horse ATG was used more frequently than rabbit ATG overall (50% vs 24%, P < 0.001), and predominance of horse ATG was most evident in the western hemisphere, in small- to medium-sized centers, and in pediatric centers. A wide variety of dose schedules for both drugs was reported. We conclude that there is some degree of variation in the definition of steroid refractoriness, especially between pediatric and nonpediatric programs, and no consensus has emerged in identifying the optimal ATG dose schedule in this setting. Bone Marrow Transplantation (2001) 28, 945–950.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Storb R, Gluckman E, Thomas ED et al. Treatment of established human graft-vs-host disease by antithymocyte globulin Blood 1974 44: 56–75

    CAS  PubMed  Google Scholar 

  2. Doney KC, Weiden PL, Storb R, Thomas ED . Treatment of graft-versus-host disease in human allogeneic marrow graft recipients: a randomized trial comparing antithymocyte globulin and corticosteroid Am J Hematol 1981 11: 1–8

    Article  CAS  PubMed  Google Scholar 

  3. Deeg HJ, Loughran TP, Storb R et al. Treatment of human acute graft-versus-host disease with antithymocyte globulin and cyclosporine with or without methylprednisolone Transplantation 1985 40: 162–166

    Article  CAS  PubMed  Google Scholar 

  4. Martin PJ, Schoch G, Fisher L et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment Blood 1990 76: 1464–1472

    CAS  PubMed  Google Scholar 

  5. Martin PJ, Schoch G, Fisher L et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment Blood 1991 77: 1821–1828

    CAS  PubMed  Google Scholar 

  6. Roy J, McGlave PB, Filipovich AH et al. Acute graft-versus-host disease following unrelated donor marrow transplantation: failure of conventional therapy Bone Marrow Transplant 1992 10: 77–82

    CAS  PubMed  Google Scholar 

  7. Dugan MJ, DeFor TE, Steinbuch M et al. ATG plus corticosteroid therapy for acute graft-versus-host disease: predictors of response and survival Ann Hematol 1997 75: 41–46

    Article  CAS  PubMed  Google Scholar 

  8. Kienast J, Ippoliti C, Mehra R et al. Dose-intensified antithymocyte globulin in steroid-resistant graft-versus-host disease after allogeneic marrow or blood stem cell transplantation Blood 1997 90: (Suppl. 1) 104a (Abstr.)

    Google Scholar 

  9. McCaul KG, Nevill TJ, Barnett MJ et al. Treatment of steroid-refractory acute graft-versus-host disease with rabbit antithymocyte globulin J Hematother 2000 9: 367–374

    Article  CAS  Google Scholar 

  10. Cragg L, Blazar BR, DeFor T et al. A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease Biol Blood Marrow Transplant 2000 6: 441–447

    Article  CAS  PubMed  Google Scholar 

  11. Oblon DJ, Felker D, Coyle K, Myers L . High-dose methylprednisolone therapy for acute graft-versus-host disease associated with matched unrelated donor bone marrow transplantation Bone Marrow Transplant 1992 10: 355–357

    CAS  PubMed  Google Scholar 

  12. Tutschka PJ, Farmer E, Beschorner WE et al. Therapy of acute graft-versus-host disease (GVHD) – Baltimore experience Exp Hematol 1981 9: (Suppl. 9) 126 (Abstr.)

    Google Scholar 

  13. Van Lint MT, Uderzo C, Locasciulli A et al. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian group for bone marrow transplantation Blood 1998 92: 2288–2293

    CAS  PubMed  Google Scholar 

  14. Martin PJ, Nelson BJ, Appelbaum FR et al. Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation Blood 1996 88: 824–830

    CAS  PubMed  Google Scholar 

  15. Raefsky EL, Gascon P, Gratwohl A et al. Biological and immunological characterization of ATG and ALG Blood 1986 68: 712–719

    CAS  PubMed  Google Scholar 

  16. Bourdage JS, Hamlin DM . Comparative polyclonal antithymocyte globulin and antilymphocyte/antilymphoblast globulin anti-CD antigen analysis by flow cytometry Transplantation 1995 59: 1194–1200

    Article  CAS  PubMed  Google Scholar 

  17. Ourahma S, Talon D, Barrou B et al. A prospective study on efficacy and tolerance of antithymocyte globulin Fresenius versus thymoglobuline Merieux after renal transplantation Transplant Proc 1997 29: 2427

    Article  CAS  PubMed  Google Scholar 

  18. Norrby J, Olausson M . A randomized clinical trial using ATG Fresenius or ATG Merieux as induction therapy in kidney transplantation Transplant Proc 1997 29: 3135–3136

    Article  CAS  PubMed  Google Scholar 

  19. Gaber AO, First MR, Tesi RJ et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation Transplantation 1998 66: 29–37

    Article  CAS  PubMed  Google Scholar 

  20. Zuckerman AO, Grimm M, Czerny M et al. Improved long-term results with thymoglobuline induction therapy after cardiac transplantation: a comparison of two different rabbit-antithymocyte globulines Transplantation 2000 69: 1890–1898

    Article  Google Scholar 

  21. Regan JF, Campbell K, Van Smith L et al. Sensitization following Thymoglobulin and Atgam rejection therapy as determined with a rapid enzyme-linked immunosorbent assay. US Thymoglobulin Multicenter Study Group Transplant Immunol 1999 7: 115–121

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported in part by an educational grant from Pharmacia and Upjohn.

Author information

Authors and Affiliations

  1. Baylor College of Medicine, Center for Cell and Gene Therapy, Houston, TX, USA

    B Hsu, R May, G Carrum, R Krance & D Przepiorka

Authors
  1. B Hsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R May
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G Carrum
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R Krance
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D Przepiorka
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hsu, B., May, R., Carrum, G. et al. Use of antithymocyte globulin for treatment of steroid-refractory acute graft-versus-host disease: an international practice survey. Bone Marrow Transplant 28, 945–950 (2001). https://doi.org/10.1038/sj.bmt.1703269

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703269

Keywords

This article is cited by

Search

Advanced search

Quick links